Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2016

21.07.2016 | Epidemiology

Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study

verfasst von: Anand K. Narayan, Kala Visvanathan, Susan C. Harvey

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Screening guidelines recommend that women with 20 % or greater lifetime risk of breast cancer undergo annual breast MRI screening to supplement mammography, irrespective of age. In patients less than 40 years, mammography is often avoided due to concerns about radiation and decreased performance. However, prior studies have been limited by large percentages of women above 40 with decreased breast density. Our purpose was to test whether adding mammography to breast MRI screening compared to breast MRI screening alone in women below 40 increases cancer detection rates. After obtaining IRB approval, chart review identified patients aged 25–40 years undergoing breast MR screening (2005–2014). Demographics, risk factors, BI-RADS assessments, background parenchymal enhancement, and mammographic breast tissue density were recorded. Cancer detection rates, short-term follow-up (BIRADS 3), image-guided biopsy (BIRADS 4,5), and PPV1–3 were calculated. 342 breast MRI exams were identified (average age was 33, 37 % were nulliparous, and 64 % had prior benign biopsy), 226 (66 %) of which underwent concurrent mammography. Risk factors included 64 % with breast cancer in first-degree relative(s), 90 % had heterogeneous or extremely dense breast tissue on mammography, and 16 % were BRCA carriers. Four invasive cancers were detected by MRI (11.7 cancers/1000 examinations, 95 % CI 8.3, 15.1). None of these was detected by mammography, and no cancers were independently identified by mammography. Breast MRI screening in high-risk women under 40 yielded elevated cancer detection rates (11.7/1000). The cancer detection rate for mammography was 0 %, suggesting that MRI alone may be useful in screening high-risk women under 40.
Literatur
1.
Zurück zum Zitat Lee CH, Dershaw DD, Kopans D et al (2010) Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 7(1):18–27CrossRefPubMed Lee CH, Dershaw DD, Kopans D et al (2010) Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 7(1):18–27CrossRefPubMed
2.
Zurück zum Zitat Berrington de Gonzalez A, Reeves G (2005) Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits. Br J Cancer 93:590–596CrossRefPubMedPubMedCentral Berrington de Gonzalez A, Reeves G (2005) Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits. Br J Cancer 93:590–596CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Checka CM, Chun JE, Schnabel FR, Lee J, Toth H (2012) The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 198(3):W292–W295CrossRefPubMed Checka CM, Chun JE, Schnabel FR, Lee J, Toth H (2012) The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 198(3):W292–W295CrossRefPubMed
5.
Zurück zum Zitat Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679CrossRefPubMed Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679CrossRefPubMed
6.
Zurück zum Zitat Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–1675CrossRefPubMed Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–1675CrossRefPubMed
7.
Zurück zum Zitat Heywang-Köbrunner SH, Bick U, Bradley WG Jr et al (2001) International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 11(4):531–546CrossRefPubMed Heywang-Köbrunner SH, Bick U, Bradley WG Jr et al (2001) International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 11(4):531–546CrossRefPubMed
8.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M et al (eds) (2016). SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD http://seer.cancer.gov/csr/1975_2013/. based on November 2015 SEER data submission, posted to the SEER web site Accessed 15 June 2016 Howlader N, Noone AM, Krapcho M et al (eds) (2016). SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD http://​seer.​cancer.​gov/​csr/​1975_​2013/​. based on November 2015 SEER data submission, posted to the SEER web site Accessed 15 June 2016
9.
Zurück zum Zitat Kuhl C, Weigel S, Schrading S et al (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28(9):1450–1457CrossRefPubMed Kuhl C, Weigel S, Schrading S et al (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28(9):1450–1457CrossRefPubMed
12.
Zurück zum Zitat Freitas V, Scaranelo A, Menezes R, Kulkarni S, Hodgson D, Crystal P (2013) Added cancer yield of breast magnetic resonance imaging screening in women with a prior history of chest radiation therapy. Cancer 119(3):495–503. doi:10.1002/cncr.27771 CrossRefPubMed Freitas V, Scaranelo A, Menezes R, Kulkarni S, Hodgson D, Crystal P (2013) Added cancer yield of breast magnetic resonance imaging screening in women with a prior history of chest radiation therapy. Cancer 119(3):495–503. doi:10.​1002/​cncr.​27771 CrossRefPubMed
13.
Zurück zum Zitat Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. New Engl J Med 351(5):427–437CrossRefPubMed Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. New Engl J Med 351(5):427–437CrossRefPubMed
15.
Zurück zum Zitat Lehman CD, Lee CI, Loving VA, Portillo MS, Peacock S, DeMartini WB (2012) Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age. AJR Am J Roentgenol 199(5):1169–1177. doi:10.2214/AJR.12.8842 CrossRefPubMed Lehman CD, Lee CI, Loving VA, Portillo MS, Peacock S, DeMartini WB (2012) Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age. AJR Am J Roentgenol 199(5):1169–1177. doi:10.​2214/​AJR.​12.​8842 CrossRefPubMed
17.
Zurück zum Zitat Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB (2014) Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol 32(22):2304–2310. doi:10.1200/JCO.2013.52.5386 CrossRefPubMed Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB (2014) Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol 32(22):2304–2310. doi:10.​1200/​JCO.​2013.​52.​5386 CrossRefPubMed
Metadaten
Titel
Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study
verfasst von
Anand K. Narayan
Kala Visvanathan
Susan C. Harvey
Publikationsdatum
21.07.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3912-y

Weitere Artikel der Ausgabe 3/2016

Breast Cancer Research and Treatment 3/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.